answers to your
Be ready for future of HTA health economics landscape in France and discover the French ICER threshold.More
Creativ-Ceutical and Continuum Clinical form Strategic Alliance
Industry leaders in developing evidence of medical product value collaborate to serve clients.
Take a look at our scientific contributions to ISPOR 20th Annual International Meeting in PhiladelphiaMore
Understand the difference between HAS and NICE health economic requirements.
Identify the grounds for differentiation and be ready for successful submission.
We have just opened a new office in Beijing, it's our second office based in Asia!More
ISPOR endorses Creativ-Ceutical's team on academic research for their article published in Value in Health.More
Submit an article to the JMAHP, the new open access journal of market access and health policy supported by Creativ-Ceutical.More
The EU Commission requested Creativ-Ceutical to provide a forecast model to assess the impact of new patented medicinal products versus medicinal products going off-patent until 2016, and in 7 EU countries.More
Have a look at our recent publications.More
“ The innovative model developed for pharmaceutical expenditure forecast allowed to inform the European Commission on how Member States' public pharmaceutical expenditures are likely to evolve over the next few years, both from medicinal products going off patent and from new patent medicinal products.”EU Commission DG SANCO
“Creativ-Ceutical has helped Air Liquide Santé International to assess new indications for long-known molecule. Hard-workers and based on strict methodology, they have been great consultants and proven highest added value to internal thinking. ”International Medical Director, Air Liquide Santé International World Business Line